Current Cancer Drug Targets · 2020 · 13 citations · 55 references
MedicineOncologyPharmacologyApoptosisMolecular OncologyMolecular PharmacologyApoptosis In CancerApoptosis PharmacologyApoptosis RegulationApoptotic SignalingColorectal CancerEndoplasmic Reticulum Stress-induced ApoptosisAnnexin V AssaysApoptotic Signaling In CancerPerk Signaling PathwayPro-apoptotic AgentsProtein Kinase InhibitorsSignaling Pathway RegulationUnfolded Protein ResponseUnfolded Protein Response-mediated Apoptosis
BACKGROUND: Colorectal cancer constitutes one of the most common cancer with a high mortality rate. The newest data has reported that activation of the pro-apoptotic PERK-dependent unfolded protein response signaling pathway by small-molecule inhibitors may constitute an innovative anti-cancer treatment strategy. OBJECTIVE: In the presented study, we evaluated the effectiveness of the PERK-dependent unfolded protein response signaling pathway small-molecule inhibitor 42215 both on HT-29 human colon adenocarcinoma and CCD 841 CoN normal human colon epithelial cell lines. METHODS: Cytotoxicity of the PERK inhibitor was evaluated by the resazurin-based and lactate dehydrogenase (LDH) tests. Apoptotic cell death was measured by flow cytometry using the FITCconjugated Annexin V to indicate apoptosis and propidium iodide to indicate necrosis as well as by colorimetric caspase-3 assay. The effect of tested PERK inhibitor on cell cycle progression was measured by flow cytometry using the propidium iodide staining. The level of the phosphorylated form of the eukaryotic initiation factor 2 alpha was detected by the Western blot technique. RESULTS: Obtained results showed that investigated PERK inhibitor is selective only toward cancer cells, since inhibited their viability in a dose- and time-dependent manner and induced their apoptosis and G2/M cell cycle arrest. Furthermore, 42215 PERK inhibitor evoked significant inhibition of eIF2α phosphorylation within HT-29 cancer cells. CONCLUSION: Highly-selective PERK inhibitors may provide a ground-breaking, anti-cancer treatment strategy via activation of the pro-apoptotic branch of the PERK-dependent unfolded protein response signaling pathway.
55
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2018 · 17K citations · Full text
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2017 · 15K citations · Full text
Global patterns and trends in colorectal cancer incidence and mortality
Melina Arnold, Mónica S. Sierra, Mathieu Laversanne et al. · Gut · 2016 · 5.3K citations · Full text
Kyosuke Haze, Hiderou Yoshida, Hideki Yanagi et al. · Molecular Biology of the Cell · 1999 · 2K citations
The cell: a molecular approach
Choice Reviews Online · 1997 · 1.5K citations